Physician

Kaushal Sondarwa, MD

According to 2025 Medicare claims, Kaushal Sondarwa, MD (NPI: 1225397250) practices nephrology in the San Angelo, TX market, with the plurality of this provider's patient population coming from Tom Green, TX. This provider's primary affiliated billing organization is SHANNON CLINIC (NPI: 1770587149; TIN: 752600873) and primary practice location at 76903-5904. Sondarwa is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Sondarwa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 447 traditional Medicare patients, billed 2,884 HCPCS/CPT codes, and received $174,889 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,275 prescription claims across 246 beneficiaries totaling $168,392 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 160 claims. Open Payments data shows 4 records totaling $190. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $10,574 to $168,392. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	101	510	$26,459
2018	507	4,042	$181,133
2019	555	5,193	$200,565
2020	542	4,564	$168,889
2021	536	2,574	$166,463
2022	479	2,447	$162,752
2023	468	2,475	$164,008
2024	447	2,884	$174,889

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	33	124	$10,574
2016	12	46	$4,913
2017	19	73	$7,042
2018	105	493	$60,253
2019	148	829	$79,609
2020	162	851	$44,837
2021	168	844	$60,565
2022	207	1,046	$104,212
2023	219	1,073	$108,960
2024	246	1,275	$168,392

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	47	$1,636
2019	N/R	153	$5,564
2020	N/R	158	$5,037
2021	N/R	96	$2,108
2022	N/R	116	$2,007
2023	N/R	116	$1,628
2024	N/R	160	$2,189

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	76	86	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	229	356	$93
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	98	297	$63
90935	Hemodialysis procedure with physician evaluation	54	147	$58
36415	Insertion of needle into vein for collection of blood sample	206	527	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	25	930	$48,588
Farxiga	Dapagliflozin Propanediol	47	2,250	$42,383
Jardiance	Empagliflozin	19	810	$15,546
Veltassa	Patiromer Calcium Sorbitex	11	466	$13,852
Sevelamer Carbonate	Sevelamer Carbonate	32	2,340	$9,005

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	40	$678
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	35	$539
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	41	$489
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	44	$483

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$190	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kaushal Sondarwa, MD?

Tedicare shows public-source Medicare data for Kaushal Sondarwa, MD (NPI 1225397250), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kaushal Sondarwa, MD have ACO affiliation data?

Kaushal Sondarwa, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Kaushal Sondarwa, MD?

Kaushal Sondarwa, MD is linked to SHANNON CLINIC (billing NPI 1770587149) in the available physician profile data.

Does Kaushal Sondarwa, MD have Open Payments data?

Kaushal Sondarwa, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.